Heterogeneous electro-Fenton process for degradation of bisphenol A using a new graphene/cobalt ferrite hybrid catalyst.

A simple, efficient, environmentally friendly, and inexpensive synthesis route was developed to obtain a magnetic nano-hybrid (GH) based on graphene and cobalt ferrite. Water with a high content of natural organic matter (NOM) was used as solvent and a source of carbon. The presence of NOM in the composition of GH was confirmed by FTIR and Raman spectroscopy, which evidenced the formation of graphene, as also corroborated by XRD analyses. The diffractograms and TEM images showed the formation of a hybrid nanomaterial composed of graphene and cobalt ferrite, with crystallite and particle sizes of 0.83 and 4.0 nm, respectively. The heterogeneous electro-Fenton process (EF-GH) achieved 100% degradation of bisphenol A (BPA) in 50 min, with 80% mineralization in 7 h, at pH 7, using a current density of 33.3 mA cm-2. The high catalytic performance was achieved at neutral pH, enabling substantial reduction of the costs of treatment processes. This work contributes to understanding the role of NOM in the synthesis of a magnetic nano-hybrid based on graphene and cobalt ferrite, for use in heterogeneous catalysis. This nano-hybrid has excellent potential for application in the degradation of persistent organic pollutants found in aquatic environments.

Evaluation of the bioequivalence of two formulations containing the combination of 400 mg of acetaminophen (paracetamol), 4 mg of phenylephrine and 4 mg of chlorpheniramine in capsules: open-label, three-way crossover study, partially replicated in healthy volunteers of both sexes

This study was carried out in order to compare the relative bioavailability of two different formulations containing 400 mg of acetaminophen + 4 mg of phenylephrine hydrochloride + 4 mg of chlorpheniramine maleate, Test formulation (Cimegripe®) and Reference formulation (Resfenol®) in 84 healthy volunteers of both sexes under fasting conditions. The study was conducted in a single dose, randomized, open-label, crossover 3-way and partially replicated. The tolerability was evaluated by the monitoring of adverse events and vital signs, results of clinical and laboratory tests. Plasma concentrations were quantified by validated bioanalytical methods using the ultra-performance liquid chromatography coupled to tandem mass spectrometry. The Cmax, Tmax, AUC0-t, AUC0-inf, T1/2 and Kel pharmacokinetic parameters were calculated from these obtained concentrations. The 90% confidence intervals were constructed for the ratio reference/test from the geometric average of the Cmax and AUC parameters which were comprised between 80% and 125%. Only the Cmax parameter of the phenylephrine was applied the scaled average bioequivalence due to the intraindividual coefficient of variation > 30% obtained, thus extending the acceptance limits of the interval. It can be concluded that the two formulations were bioequivalent in terms of rate and absorption extent and thus interchangeable